Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P531: MIDOSTAURIN PLUS 7 + 3 O...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN FLT3-ITD MUTATED AML

Bibliographic Details
Main Authors: Mar Tormo, Marina Diaz-Beya, Paola Beneit, Ainhoa Fernández Moreno, Montserrat Arnan, Ana Garrido Diaz, Susana Vives, Maria García Fortes, Antonia Sampol, Jorge Labrador, Antonio Garcia-Guiñon, Carmen Botella, Juan Miguel Bergua Burgues, Mayte Olave, Maria Luz Amigo, Xavier Ortín, Ferrand Ferran Vall-Llovera, Maria Pereiro, Josefina Serrano, Maria Jose Sayas Lloris, Almudena De Laiglesia Lorenzo, Juan Jose Bargay Lleonart, Maria Luisa Calabuig Muñoz, Adolfo De La Fuente
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000969032.40255.74
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000969032.40255.74

Similar Items

  • P523: MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY IN FLT3 MUTATED AML. “REAL LIFE” DATA VERSUS THE RATIFY STUDY
    by: A. De La Fuente, et al.
    Published: (2022-06-01)
  • MIDOSTAURIN ADDED TO CYTOSINE ARABINOSIDE PLUS IDARUBICIN (“7+3”) IN NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA
    by: P Barreto, et al.
    Published: (2021-10-01)
  • Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function
    by: Denise Wolleschak, et al.
    Published: (2014-06-01)
  • S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDOMIZED CLINICAL TRIAL COMPARING STANDARD CHEMOTHERAPY PLUS QUIZARTINIB VERSUS PLACEBO IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD WILD-TYPE AML
    by: Pau Montesinos, et al.
    Published: (2023-08-01)
  • Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
    by: Frank G. Rücker, et al.
    Published: (2024-12-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs